Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | Exe VP&Chief Ethics & ComplOff | May 10, 2012 | May 10, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 10, 2012 · Filed May 10, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,540 |
Ending reported balance
After 2012-05-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2012-05-10 · Exercise / conversion · Acquired 27,377 · Balance 100,917 Row 2 · 2012-05-10 · Sale · Disposed 27,377 · Balance 73,540 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.66 · Expires 2015-04-30 | Direct | 0 |
Reported balance
After 2012-05-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2012-05-10 · Exercise / conversion · Disposed 27,377 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectAs Custodian | 252 |
Reported balance
Holding disclosure · report date 2012-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 252 |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 3,753.1015 |
Reported balance
Holding disclosure · report date 2012-05-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,753.1015 F1: Includes shares acquired and dividends earned through April 6, 2012 in the MSD Employee Savings and Security Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares acquired and dividends earned through April 6, 2012 in the MSD Employee Savings and Security Plan, a 401(k) plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerStock Option (right to buy) · Derivative | 4,824 | $0.00 Strike: $19.23 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 10 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,176 Underlying: Common Stock · 4,824 shares Expires 2013-05-18 F11 · derivative.exercise_price: The option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08. F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerStock Option (right to buy) · Derivative | 5,262 | $0.00 Strike: $20.70 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 9 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,738 Underlying: Common Stock · 5,262 shares Expires 2015-04-24 F10 · derivative.exercise_price: The option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69. F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerStock Option (right to buy) · Derivative | 5,262 | $0.00 Strike: $18.20 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 8 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,738 Underlying: Common Stock · 5,262 shares Expires 2014-02-22 F9 · derivative.exercise_price: The option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95. F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerStock Option (right to buy) · Derivative | 2,132 | $0.00 Strike: $34.68 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 7 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,168 Underlying: Common Stock · 2,132 shares Expires 2012-02-24 F8 · derivative.exercise_price: The option price for the grant expiring 2/24/12 will convert from $34.68 to $38.01. F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerStock Option (right to buy) · Derivative | 1,467 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 6 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,133 Underlying: Common Stock · 1,467 shares Expires 2011-02-25 F7 · derivative.exercise_price: The option price for the grant expiring 2/25/11 will convert from $40.05 to $43.90. F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerStock Option (right to buy) · Derivative | 6,139 | $0.00 Strike: $54.25 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · derivative · entry 5 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,861 Underlying: Common Stock · 6,139 shares Expires 2011-01-01 F4 · derivative.exercise_price: The option price for the grant expiring 1/01/11 will convert from $54.25 to $59.47. F6 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. F5 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock - 401(k) Plan | 3,377.3284 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · nonDerivative · entry 4 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 3,377.3284 F3 · price: Received as part of the Agreement and Plan of Merger by and among, inter alia, Merck Sharp & Dohme Corp. and Merck & Co., Inc. (formerly Schering-Plough Corporation) in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. common stock held under the Merck Sharp & Dohme Corp. 401(k) plan. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · nonDerivative · entry 3 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Indirect · As Custodian Disclosed balance after: 252 F1 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerCommon Stock | 33,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · nonDerivative · entry 2 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,855 F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement. Read SEC document |
| November 03, 2009 Filed Nov 7, 2009 00:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 4,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021905 · doc4.xml · nonDerivative · entry 1 Bowles Richard S III · CIK 0001475384 · Exe V-P & Chief Compl Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,503 F1 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck. Read SEC document |
| November 03, 2009 Filed Jan 29, 2010 21:54 UTC Amendment | Merck & Co., Inc. (MRK) · Entity 2807 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-10-005623 · doc4a.xml · nonDerivative · entry 2 Bowles Richard S III · CIK 0001475384 · Ex.VP&ChiefComp.Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,569 F3 · shares: Pursuant to the terms of the Issuer's 2006 Stock Incentive Plan, the shares will become payable on December 31, 2011 provided that the reporting person remains continuously employed by the Issuer through that date, or, if sooner, upon the reporting person's involuntary termination of employment other than for cause. F2 · balance_after: Reflects beneficial ownership as of November 3, 2009. Read SEC document |
| November 03, 2009 Filed Jan 29, 2010 21:54 UTC Amendment | Merck & Co., Inc. (MRK) · Entity 2807 | GrantCommon Stock | 10,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-10-005623 · doc4a.xml · nonDerivative · entry 1 Bowles Richard S III · CIK 0001475384 · Ex.VP&ChiefComp.Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,469 F1 · shares: Distribution of net after tax shares of common stock from performance-based share units granted on February 26, 2007. Pursuant to the terms of the Issuer's 2006 Stock Incentive Plan, the shares vested upon the completion of the transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, Merck Sharp & Dohme Corp.(formerly Merck & Co., Inc.) and Merck & Co., Inc. (formerly Schering-Plough Corporation)(the "Transaction"). F2 · balance_after: Reflects beneficial ownership as of November 3, 2009. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.